Phase 1 study of alisertib (MLN8237) and weekly irinotecan in adults with advanced solid tumors | Zendy

Thomas J. Semrad | Zendy; Edward Kim | Zendy; I-Yeh Gong | Zendy; Tianhong Li | Zendy; Scott Christensen | Zendy; Mili Arora | Zendy; Jonathan W. Riess | Zendy; David R. Gandara | Zendy; Karen Kelly | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Phase 1 study of alisertib (MLN8237) and weekly irinotecan in adults with advanced solid tumors

Author(s) -

Thomas J. Semrad,

Edward Kim,

I-Yeh Gong,

Tianhong Li,

Scott Christensen,

Mili Arora,

Jonathan W. Riess,

David R. Gandara,

Karen Kelly

Publication year - 2021

Publication title -

cancer chemotherapy and pharmacology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.112

H-Index - 111

eISSN - 1432-0843

pISSN - 0344-5704

DOI - 10.1007/s00280-021-04293-3

Subject(s) - irinotecan , medicine , tolerability , neutropenia , population , febrile neutropenia , response evaluation criteria in solid tumors , adverse effect , gastroenterology , pharmacokinetics , phases of clinical research , cancer , colorectal cancer , oncology , surgery , clinical trial , chemotherapy , environmental health

Aurora kinases are overexpressed or amplified in numerous malignancies. This study was designed to determine the safety and tolerability of the Aurora A kinase inhibitor alisertib (MLN8237) when combined with weekly irinotecan.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research